Hertzberg 2001.

Methods	BUPROPION Randomized controlled trial Setting: Veterans Affairs Medical Centre (VAMC), USA Recruitment: VAMC outpatient volunteers
Participants	15 male veterans with Post Traumatic Stress Disorder, av age 50, av CPD 33
Interventions	1. Bupropion 300 mg/day, 12w begun at least 1w before TQD. 2. Placebo Both arms: individual counselling pre‐quit, weeks 1,2,4,8,12.
Outcomes	Abstinence at 6m, prolonged, validated at weeks 2, 8, 12. Validation: CO <= 10ppm Paper includes as abstinent one person with a slip at week 12
Notes	2 of the successful quitters were taking bupropion at 6m, prescribed after end of study. Funding: Glaxo Wellcome Inc, National Cancer Institute
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization method not described.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double‐blind, no further information provided.
Incomplete outcome data (attrition bias) All outcomes	High risk	Uneven attrition between arms; very high percentage lost to follow‐up in placebo group. 30% of the participants receiving bupropion SR did not complete the full 12‐week trial; 80% of the placebo group failed to complete the trial and were considered to have resumed smoking.